Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 7;5(1):e000331.
doi: 10.1136/bmjophth-2019-000331. eCollection 2020.

Ocular side effects of antirheumatic medications: a qualitative review

Clara M Castillejo Becerra #  1 , Yue Ding #  2 , Beatrice Kenol  2 , Andrew Hendershot  3 , Alexa Simon Meara  4
Affiliations
Review

Ocular side effects of antirheumatic medications: a qualitative review

Clara M Castillejo Becerra et al. BMJ Open Ophthalmol. .

Abstract

Topic: This paper reviews the ocular side effects of medications used in the treatment of rheumatological conditions.

Clinical relevance: Rheumatic diseases are inflammatory conditions that may affect the skin, blood vessels, joints, muscles and internal organs. Immunosuppressive agents are often used as treatment and while powerful, they carry side effects and toxicities that need careful monitoring. Ophthalmic complications have been reported with the use of antirheumatic medications; however, there is a lack of literature synthesising these reports. This paper addresses this gap and hopes to inform both rheumatologists and ophthalmologists as they work together on the management of patients with rheumatological conditions.

Methods: PubMed literature search was conducted from November to September 2019 searching for ocular side effects with the use of 25 rheumatological drugs.

Results: A total of 111 papers were included in this review. Adverse side effects were divided into non-infectious and infectious causes. Traditional disease-modifying antirheumatic drugs (DMARDs) were associated with pruritus, irritation and dryness of the conjunctiva while biologic DMARDS showed reports of new-onset/recurrent uveitis and demyelinating conditions. Infectious side effects included episodes of cytomegalovirus retinitis, toxoplasmic chorioretinitis and endophthalmitis. Other serious side effects were encountered and included in this review.

Conclusion: The goal of this paper is to inform healthcare providers about potential ocular side effects from rheumatological medications. Healthcare providers are encouraged to learn more about these ophthalmic complications and find relevance within their clinical practice.

Keywords: immunology; pharmacology; treatment medical.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Flow diagram of study selection process.
See this image and copyright information in PMC

References

    1. Marmor MF, Kellner U, Lai TYY, et al. . Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 2016;123:1386–94. 10.1016/j.ophtha.2016.01.058 - DOI - PubMed
    1. Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin 1992;10:505–12. 10.1016/S0733-8635(18)30318-8 - DOI - PubMed
    1. Hoppmann RA, Peden JG, Ober SK. Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Aseptic meningitis, psychosis, and cognitive dysfunction. Arch Intern Med 1991;151:1309–13. - PubMed
    1. Fraunfelder FW, Solomon J, Mehelas TJ. Ocular adverse effects associated with cyclooxygenase-2 inhibitors. Arch Ophthal 2006;124:277–9. 10.1001/archopht.124.2.277 - DOI - PubMed
    1. Murad MH, Sultan S, Haffar S, et al. . Methodological quality and synthesis of case series and case reports. BMJ Evidence-Based Medicine 2018;23:60–3. 10.1136/bmjebm-2017-110853 - DOI - PMC - PubMed